{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.0","upperLimit":"8.7","value":"1.12"},{"groupId":"OG001","lowerLimit":"0.9","upperLimit":"5.9","value":"1.12"},{"groupId":"OG002","lowerLimit":"2.83","upperLimit":"2.83","value":"2.83"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"description":"Time to clinical benefit was defined as the time from first dose of therapy to first documented confirmed response of minimal response (MR) or better.","dispersionType":"Full Range","groups":[{"description":"Patients with moderate renal impairment (eGFR ≥30 to \\<45 mL/min/1.73m²) and a starting dose of melflufen of 40 mg.","id":"OG000","title":"Cohort 1a, Melflufen 40 mg"},{"description":"Patients with moderate renal impairment (eGFR ≥30 to \\<45 mL/min/1.73m²) and a starting dose of melflufen of 30 mg.","id":"OG001","title":"Cohort 1b, Melflufen 30 mg"},{"description":"Patients with severe renal impairment (eGFR ≥15 to \\<30 mL/min/1.73m²) and a starting dose of melflufen of 20 mg.","id":"OG002","title":"Cohort 2a, Melflufen 20 mg"}],"paramType":"MEDIAN","populationDescription":"This analysis included patients who achieved a best response of MR or better.","reportingStatus":"POSTED","timeFrame":"Patients were assessed for response after each cycle. After discontinuation of therapy, patients continued to be assessed until documented progression (confirmed on 2 consecutive assessments) or initiation of subsequent therapy (max duration 127.1 weeks).","title":"Time to Clinical Benefit","type":"SECONDARY","unitOfMeasure":"months"}